Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Peter Greenleaf Sells 797 Shares

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Director Peter Greenleaf sold 797 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $20.92, for a total transaction of $16,673.24. Following the transaction, the director directly owned 24,681 shares of the company’s stock, valued at $516,326.52. The trade was a 3.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pelthos Therapeutics Stock Up 19.5%

PTHS opened at $24.38 on Tuesday. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.05 and a quick ratio of 1.15. The firm’s 50 day moving average is $22.86. Pelthos Therapeutics Inc. has a twelve month low of $9.00 and a twelve month high of $54.29. The stock has a market capitalization of $81.92 million, a PE ratio of -1.17 and a beta of 3.93.

Analyst Ratings Changes

PTHS has been the subject of several recent research reports. Zacks Research upgraded shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 24th. Roth Mkm cut their target price on shares of Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Cantor Fitzgerald initiated coverage on shares of Pelthos Therapeutics in a research report on Wednesday, April 1st. They set an “overweight” rating and a $50.00 target price for the company. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Pelthos Therapeutics in a research report on Thursday, March 19th. Finally, Piper Sandler initiated coverage on shares of Pelthos Therapeutics in a research report on Friday, February 27th. They set an “overweight” rating and a $48.00 target price for the company. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $55.00.

Hedge Funds Weigh In On Pelthos Therapeutics

A number of hedge funds have recently modified their holdings of PTHS. Persistent Asset Partners Ltd boosted its position in shares of Pelthos Therapeutics by 150.0% in the fourth quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock worth $186,000 after purchasing an additional 3,604 shares during the period. Millennium Management LLC bought a new position in shares of Pelthos Therapeutics in the fourth quarter worth approximately $343,000. Geode Capital Management LLC boosted its position in shares of Pelthos Therapeutics by 31.9% in the fourth quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock worth $422,000 after purchasing an additional 3,295 shares during the period. Knott David M Jr boosted its position in shares of Pelthos Therapeutics by 215.5% in the fourth quarter. Knott David M Jr now owns 19,281 shares of the company’s stock worth $598,000 after purchasing an additional 13,169 shares during the period. Finally, Diadema Partners LP boosted its position in shares of Pelthos Therapeutics by 138.1% in the fourth quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock worth $775,000 after purchasing an additional 14,502 shares during the period. 77.96% of the stock is currently owned by institutional investors.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).